TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28949973
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone pessaries (100 mg)
Study: 21839850
Drug: Olodaterol 2
Normalized name: OLODATEROL 2.5MCG/ACTUAT 14D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olodaterol 2 μg
Study: 24966672
Drug: Olodaterol 5
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 5 μg
Study: 24966672
Drug: Olodaterol 10
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 10 μg
Study: 21839850
Drug: Olodaterol 20
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 20 μg
Study: 19884816
Drug: Pantoprazole, clarithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, clarithromycin, and amoxicillin (PCA) for 14 days
Study: 19884816
Drug: Ranitidine-bismuth citrate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine-bismuth citrate, clarithromycin, and amoxicillin (RCA) for 14 days
Study: 17265148
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of olanzapine
Study: 11224891
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone sodium succinate (MPSS)
Study: 3085698
Drug: Nitradisc 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitradisc 32 mg patch
Study: 3085698
Drug: Transiderm‐Nitro 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transiderm‐Nitro 50 mg patch
Study: 3085698
Drug: Nitro-Dur 104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitro-Dur 104 mg patch
Study: 3085698
Drug: Nitrobid 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrobid 2% ointment
Study: 29732536
Drug: Cognitive-Behavioral Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Treatment of Insomnia (CBTi)
Study: 24513113
Drug: 0F-200 (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0F-200 (no fluoride in 200 ml milk)
Study: 24513113
Drug: 1.5F-100 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5F-100 (1.5 mg fluoride in 100 ml milk)
Study: 24513113
Drug: 3F-100 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3F-100 (3 mg fluoride in 100 ml milk)
Study: 24513113
Drug: 1.5F-200 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5F-200 (1.5 mg fluoride in 200 ml milk)
Study: 24513113
Drug: 3F-200 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3F-200 (3 mg fluoride in 200 ml milk)
Study: 24513113
Drug: Fluoride in
Normalized name: sulfur hexafluoride intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride in 100 ml milk
Study: 24513113
Drug: All fluoridated
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All fluoridated milk treatments
Study: 22934395
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of autologous blood (2 mL/acupoint, once a week for 4 weeks)
Study: 22934395
Drug: Motilium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motilium (10 mg, 3 times daily for 4 weeks)
Study: 22934395
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of autologous blood
Study: 17599483
Drug: Strict glycemic
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glycemic control protocol (insulin administration)
Study: 15595583
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural anaesthesia with bupivacaine 0.25% and sufentanil 0.001 mg/mL
Study: 11757212
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone (bolus of 70 to 140 mg)
Study: 11757212
Drug: Oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone (300 to 600 mg)
Study: 8059021
Drug: Verapamil (V)
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (V) 80 mg/8 h per os before surgery and 5 mg/4-6 h slow infusion during the next intra- and postoperative 24-36 h
Study: 6313597
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of acyclovir (400 to 1200 mg/m2/dose)
Study: 6313597
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acyclovir and human alpha interferon (2 to 40 X 10(4) units/kg/day)
Study: 28248690
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment (12 twice-weekly 45-min sessions focusing on trigger point release)
Study: 17908625
Drug: Brief chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief chemotherapy and involved-field radiation
Study: 17908625
Drug: Brief chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief chemotherapy alone
Study: 16296963
Drug: Alcohol/chlorhexidine hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol/chlorhexidine hand hygiene solution (ACHRS)
Study: 11937123
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (embryo transfer without any supportive therapy)
Study: 9742523
Drug: IL-2 7
Normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 7 x 10(5) U, 5-fluorouracil (5-FU) 250 mg/day continuous infusion, mitomycin C (MMC) 4 mg once weekly for unresectable liver metastases
Study: 9742523
Drug: IL-2 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 1.4 to 2.1 x 10(6) U, 5-FU 250 mg, MMC 2 to 4 mg weekly for 6 months for resectable liver metastases
Study: 2684552
Drug: Ceftriaxone, 2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 2g IV once daily
Study: 2684552
Drug: Cefotaxime, 2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime, 2g IV thrice daily
Study: 866797
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of stilbestrol daily
Study: 24060817
Drug: Iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 320 mg I/mL
Study: 28045670
Drug: Iopamidol 370
Normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 370 mg I/mL
Study: 20937606
Drug: telcagepant 150
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 150 mg
Study: 10214535
Drug: zolmitriptan 5
Normalized name: zolmitriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolmitriptan 5 mg
Study: 20937606
Drug: telcagepant 300
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 300 mg vs zolmitriptan
Study: 19536906
Drug: Dasatinib 70
Normalized name: dasatinib 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 70 mg twice daily (n=101)
Study: 19536906
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib 800 mg (n=49)
Study: 15385371
Drug: 0.25% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% levobupivacaine 12.5 mg/h (5 mL/h)
Study: 15385371
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 5 mL/h via a catheter
Study: 1838978
Drug: Clarithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (250 mg twice daily for 10 days)
Study: 7998667
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 micrograms/day, administered twice daily)
Study: 7998667
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) (31.2 mg/day, administered six times per day)
Study: 6399346
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium therapy
Study: 31486166
Drug: High coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High coffee intake (>6 cups daily)
Study: 25497115
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (GRAS dose)
Study: 24481930
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 75 μg with bupivacaine
Study: 24481930
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine 150 μg with bupivacaine
Study: 12757449
Drug: Herbal supplements
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal supplements (23 commonly used)
Study: 1622642
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 2 years
Study: 20225908
Drug: Ketoprofen 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.25 mg/kg
Study: 20225908
Drug: Ketoprofen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.5 mg/kg
Study: 20225908
Drug: Ketoprofen 1
Normalized name: ketoprofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 1 mg/kg
Study: 10100174
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (single dose, 20 g, 34 mg phytoestrogens)
Study: 10100174
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (twice-daily, 20 g, 34 mg phytoestrogens)
Study: 1687055
Drug: Long-acting GnRHa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting GnRHa (D-Trp-6-LHRH) microcapsules administered intramuscularly at menstruation
Study: 1687055
Drug: FSH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH and hMG from day 3 of the cycle without GnRHa pre-treatment
Study: 6475827
Drug: Commercial ergogenic
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial ergogenic supplement (vitamin, mineral, amino acid, and unsaturated fatty acid complex) administered at a dose of three capsules daily for 4 weeks.
Study: 6475827
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 4 weeks.
Study: 20862645
Drug: Pharmacological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatments (modulation of the glutamate system, blocking of serotonin 5-HT-3/2a receptors)
Study: 18173155
Drug: Lin'erlai Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lin'erlai Prescription (LEL)
Study: 16089148
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of xiaoke shen'an capsule and conventional western medicine
Study: 11994935
Drug: Standardized verbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized verbal administration of GDS-SF
Study: 11994935
Drug: Non-standardized verbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-standardized verbal administration of GDS-SF
Study: 6246005
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (pivmecillinam and pivampicillin)
Study: 28810061
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg IR CTC (equivalent to 88 mg tramadol and 112 mg celecoxib)
Study: 28810061
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg IR tramadol
Study: 28888220
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg celecoxib
Study: 28810061
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg IR tramadol and 100 mg celecoxib
Study: 25970619
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AIMS and NSMDA
Study: 19819790
Drug: Gabapentin 800
Normalized name: gabapentin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 800 mg/daily for 30 days
Study: 19819790
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg/daily for 30 days
Study: 9585270
Drug: Propofol IV
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol IV infusion titrated to electroencephalographic burst suppression during CPB
Study: 9585270
Drug: Propofol IV
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol IV infusion
Study: 7618427
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pentazocine
Study: 2729164
Drug: Pure beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure beta-carotene (12 or 30 mg)
Study: 2729164
Drug: Carrots (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrots (270 g)
Study: 2729164
Drug: Broccoli (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli (600 g)
Study: 2729164
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (180 g)
Study: 665561
Drug: Egg formula
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg formula diet with higher protein level (0.6 g/kg)
Study: 665561
Drug: Rural Guatemalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rural Guatemalan diet (0.0875 g protein/kg)
Study: 24089589
Drug: Strength Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength Training + Testosterone Treatment (ST + TT)
Study: 2468628
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information
Study: 15841789
Drug: Written and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written and oral information
Study: 9924533
Drug: Single infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of 5 mg/kg ABLC (Group A)
Study: 9924533
Drug: Two infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two infusions of 5 mg/kg ABLC given 5 days apart (Group B)
Study: 9924533
Drug: Two infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two infusions of 5 mg/kg ABLC on consecutive days (Group C)
Study: 9924533
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose ABLC (10-15 mg/kg.day) for treatment failures
Study: 9924533
Drug: Conventional amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional amphotericin B (0.75-1.0 mg/kg on alternate days over 30-34 days)
Study: 30306284
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen at 7 L/min
Study: 30306284
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen at 12 L/min
Study: 28073680
Drug: Simultaneous initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Simultaneous initiation of Vitamin B12 and Folate supplementation (within 24 hours of chemotherapy initiation)
Study: 26196407
Drug: ARB/TZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB/TZ combination therapy
Study: 26196407
Drug: ARB/CCB combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB/CCB combination therapy
Study: 17307706
Drug: SSRIs (sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (sertraline, citalopram, paroxetine)
Study: 17307706
Drug: GABAergic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABAergic agents (vigabatrin, tiagabine, topiramate, phenobarbitone)
Study: 9681342
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon gamma, 50 microg/m2, daily subcutaneous injection
Study: 8595638
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg BID
Study: 8595638
Drug: Amoxicillin/clavulanate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500 mg TID
Study: 322491
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium (550 mg initial dose followed by 275 mg every six hours for a maximum of five days)
Study: 25467017
Drug: Imetelstat (9.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat (9.4 mg/kg on days 1 and 8 of a 21-day cycle)
Study: 21820095
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of drug-eluting stents (DES) in patients with DM
Study: 21820095
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of drug-eluting stents (DES) in patients without DM
Study: 17527093
Drug: Nucleoside-sparing regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside-sparing regimen (lopinavir/ritonavir at 533/133 mg twice a day and efavirenz at 600 mg/d)
Study: 15103923
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with 5-ml dose of 1% lidocaine injected into the periprostatic nerve plexus at 3 minutes before the procedure
Study: 15103923
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with 5-ml dose of 1% lidocaine
Study: 11473488
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + Hormone Replacement Therapy (ExHRT)
Study: 9711449
Drug: Montelukast 5
Normalized name: montelukast 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5 mg/day
Study: 3289850
Drug: Propionibacterium granulosum
Normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionibacterium granulosum KP-45 (10 mg infusion for at least 3 days before operation)
Study: 21315003
Drug: Continuous blood
Normalized name: Dexcom G6 Receiver Continuous Blood-Glucose M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous blood purification (CBP) with continuous veno-venous hemofiltration (CVVH) for 72 hours, ultrafiltrate volume 40 ml×kg(‐1)×h(‐1)
Study: 21315003
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment according to international guidelines)
Study: 19720365
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral cholera vaccine 638 (2 x 10(9) CFU)
Study: 15376518
Drug: 100-microA, 20-s
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-microA, 20-s current pulses through saturated 20.4% NaCl solution
Study: 11575110
Drug: GTR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTR and antibiotics (minocycline ointment locally, doxycycline and amoxyline systemically)
Study: 30882524
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural boluses (6-mL every 45 minutes with 0.1% ropivacaine and 2 microg/mL fentanyl)
Study: 30882524
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (8 mL/h with 0.1% ropivacaine and 2 microg/mL fentanyl)
Study: 31641199
Drug: Calibrated interdental
Normalized name: CALIBRATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calibrated interdental brushes (IDBs) used daily on test sites.
Study: 24717389
Drug: Usage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usage of antidepressant medication
Study: 7363436
Drug: Disopyramide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (200 mg single dose)
Study: 7363436
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg single dose)
Study: 7363436
Drug: Chronic disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic disopyramide therapy (200 mg every 6 hours for 1 week)
Study: 7363436
Drug: Chronic propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic propranolol therapy (80 mg every 8 hours for 1 week)
Study: 7363436
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of propranolol and disopyramide
Study: 19136753
Drug: Butorphanol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (1, 1.5 and 2 mg based on body weight)
Study: 8719647
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular saline)
Study: 11464977
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg MSL-109
Study: 11464977
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg MSL-109
Study: 11464977
Drug: MSL-109 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSL-109 (60 mg and 15 mg combined) in D+/R- subgroup
Study: 11464977
Drug: MSL-109 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSL-109 (60 mg and 15 mg combined) in D+/R+ and D-/R+ subgroup
Study: 3661492
Drug: Cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin chemotherapy (75‐100 mg/m2) and concomitant radiotherapy (20.00 Gy in 1 week) followed by full course (120 mg/m2 of cisplatin and 38.40 Gy of radiation)
Study: 3661492
Drug: Full course
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full course (FC) therapy
Study: 3661492
Drug: Partial course
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial course (PC) therapy
Study: 31317668
Drug: Mepolizumab liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab liquid formulation (100 mg) administered subcutaneously via prefilled syringe or autoinjector